Del 50 - Annual Reports in Medicinal Chemistry

Platform Technologies in Drug Discovery and Validation

Inbunden, Engelska, 2017

2 909 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Platform Technologies in Drug Discovery and Validation, Volume 50, the latest release in the Annual Reports in Medicinal Chemistry series, provides timely and critical reviews of important topics in medicinal chemistry, with an emphasis on emerging topics in the biological sciences. Topics covered in this new volume include DELT, Oligos: ASO, siRNA, CRISPR, Micro-fluidic chemistry, High throughput screening, Kinase-centric computational drug development, Virtual Screening, Phenotypic screening, PROTACS, Chemical Biology, Fragment-based lead generation, Antibody-Drug Conjugates, Antibody-recruiting small molecules, Deuteration, and Peptides.

Unique for its treatment of platform technologies for medicinal chemistry and target validation
Provides a single, rich volume that summaries a broad spectrum of expertise relevant to the field
Presents state-of-the-art summaries of platform technologies

Produktinformation

Utgivningsdatum2017-11-18
Mått152 x 229 x undefined mm
Vikt1 220 g
FormatInbunden
SpråkEngelska
SerieAnnual Reports in Medicinal Chemistry
Antal sidor690
FörlagElsevier Science
MedarbetareGoodnow,RobertA.
ISBN9780128130698

Tillhör följande kategorier

Organisk kemi inom Naturvetenskap och teknik
Farmakologi inom Medicin

Robert A. Goodnow, Jr. is currently Vice President, Chemistry Innovation at Pharmaron, Inc in Boston, MA. He completed a Ph.D. in bioorganic chemistry at Columbia University, New York, USA, followed by postdoctoral training at Princeton University, New Jersey, USA. He has worked at Roche and AstraZeneca, focusing on new lead and target discovery as well as implementing chemistry technologies in support of early drug discovery. He is the editor and author of The Handbook of DNA-Encoded Chemistry, which was published in 2014 by Wiley.

1. DNA-Encoded Library Technology: A Brief Guide to Its Evolution and Impact on Drug DiscoveryRobert A. Goodnow Jr. and Christopher P. Davie2. The Chemistry of Oligonucleotide DeliveryDavid B. Rozema3. CRISPR–Cas9 for Drug Discovery in OncologySylvie M. Guichard4. Recent Advances of Microfluidics Technologies in the Field of Medicinal ChemistryLászló Ürge, Jesus Alcazar, Lena Huck and György Dormán5. High-Throughput ScreeningMary Jo Wildey, Anders Haunso, Matthew Tudor, Maria Webb and Jonathan H. Connick6. Kinase-Centric Computational Drug DevelopmentAlbert J. Kooistra and Andrea Volkamer7. Free Energy Calculation Guided Virtual Screening of Synthetically Feasible Ligand R-Group and Scaffold Modifications: An Emerging Paradigm for Lead OptimizationRobert Abel and Sathesh Bhat8. Phenotypic ScreeningAlleyn T. Plowright and Lauren Drowley9. Targeted Protein DegradationNello Mainolfi and Tim Rasmusson10. Chemical Biology in Drug DiscoveryM. Paola Castaldi, Andrea Zuhl, Piero Ricchiuto and J. Adam Hendricks11. Fragment-Based Lead DiscoveryBen J. Davis and Stephen D. Roughley12. Antibody-Drug ConjugatesAmit Kumar, Jason White, R. James Christie, Nazzareno Dimasi and Changshou Gao13. Antibody-Recruiting Small Molecules: Synthetic Constructs as ImmunotherapeuticsPatrick J. McEnaney, Christopher G. Parker and Andrew X. Zhang14. A Decade of Deuteration in Medicinal ChemistryJulie F. Liu, Scott L. Harbeson, Christopher L. Brummel, Roger Tung, Robert Silverman and Dario Doller15. From Natural Peptides to MarketClaudio D. Schteingart and Jolene L. Lau